Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Li Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3617-2627; OpenAlex author ID A5100425554. Sources: OpenAlex.

Their work

Papers
26 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
121
Papers, trials and grants by year

2013: 3 papers · 2014: 1 paper · 2015: 3 papers · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 5 papers · 2022: 4 papers · 2023: 4 papers · 2024: none · 2025: 1 paper

Papers 26

  1. Targeting PIKfyve-driven lipid metabolism in pancreatic cancer. Co-author DOI 10.1038/s41586-025-08917-z↗
  2. Germline mutations in homologous recombination repair genes among Chinese pancreatic ductal adenocarcinoma patients detected using next-generation sequencing. Co-author DOI 10.1002/mgg3.2170↗
  3. Increased glucose availability sensitizes pancreatic cancer to chemotherapy. Co-author DOI 10.1038/s41467-023-38921-8↗
  4. Uridine-derived ribose fuels glucose-restricted pancreatic cancer. Co-author DOI 10.1038/s41586-023-06073-w↗
  5. Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jitc-2022-005425↗
  6. An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms. Co-author DOI 10.1038/s41467-022-33037-x↗
  7. Differential integrated stress response and asparagine production drive symbiosis and therapy resistance of pancreatic adenocarcinoma cells. Co-author DOI 10.1038/s43018-022-00463-1↗
  8. Metabolic requirement for GOT2 in pancreatic cancer depends on environmental context. Co-author DOI 10.7554/elife.73245↗
  9. Multiomic characterization of pancreatic cancer-associated macrophage polarization reveals deregulated metabolic programs driven by the GM-CSF-PI3K pathway. Co-author DOI 10.7554/elife.73796↗
  10. An iodine-125 seed strand combined with a metal stent versus a metal stent alone for obstructive jaundice caused by pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.brachy.2020.10.004↗
  11. KLHDC7B-DT aggravates pancreatic ductal adenocarcinoma development via inducing cross-talk between cancer cells and macrophages. Co-author DOI 10.1042/cs20201259↗
  12. Nutrient profiling reveals extracellular uridine as a fuel for pancreatic cancer through uridine phosphorylase 1 Co-author DOI 10.1101/2021.06.07.447448↗
  13. LncRNA HOTAIR Promotes Cancer Stem-Like Cells Properties by Sponging miR-34a to Activate the JAK2/STAT3 Pathway in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.2147/ott.s286666↗
  14. Establishment of a Macrophage Phenotypic Switch Related Prognostic Signature in Patients With Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.619517↗
  15. Clonal Heterogeneity Supports Mitochondrial Metabolism in Pancreatic Cancer Co-author DOI 10.1101/2020.05.15.098368↗
  16. The JAM-B/c-src/MMP9 pathway is associated with progression and regulates the invasion of pancreatic cancer. Co-author DOI 10.7150/jca.40953↗
  17. Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer. Co-author DOI 10.1016/j.cmet.2019.02.001↗
  18. Establishment of a non‑coding RNAomics screening platform for the regulation of KRAS in pancreatic cancer by RNA sequencing. Co-author DOI 10.3892/ijo.2018.4560↗
  19. Whole Grain Intake Reduces Pancreatic Cancer Risk: A Meta-Analysis of Observational Studies. Co-author DOI 10.1097/md.0000000000002747↗
  20. Elevated miR-483-3p expression is an early event and indicates poor prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s13277-015-3690-x↗
  21. Coexpression of EGFR and CXCR4 predicts poor prognosis in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0116803↗
  22. [Analysis of the changes of blood glucose after radiotherapy in pancreatic cancer patients associated with diabetes mellitus and their related factors]. Last author PMID 25877316↗
  23. [Applications of genome wide association studies and whole genome sequencing in pancreatic cancer]. Co-author PMID 24742581↗
  24. Alleviating visceral cancer pain in patients with pancreatic cancer using cryoablation and celiac plexus block. Co-author DOI 10.1016/j.cryobiol.2012.12.002↗
  25. Early manifestations of pancreatic cancer: the effect of cancer-nerve interaction. Co-author DOI 10.1016/j.mehy.2013.05.010↗
  26. MicroRNA 23b regulates autophagy associated with radioresistance of pancreatic cancer cells. Co-author DOI 10.1053/j.gastro.2013.07.048↗

Closest collaborators

The 25 strongest of 121 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Costas Andreas Lyssiotis · 9 shared papers, 2019–2025 · strength 1.03
  2. Marina Pasca di Magliano · 8 shared papers, 2019–2025 · strength 0.91
  3. Christopher J. Halbrook · 7 shared papers, 2019–2023 · strength 0.74
  4. Matthew H. Ward · 3 shared papers, 2021–2023 · strength 0.37
  5. Zeribe C. Nwosu · 3 shared papers, 2021–2023 · strength 0.34
  6. Nina G. Steele · 3 shared papers, 2022 · strength 0.34
  7. Jennifer P. Morton · 3 shared papers, 2019–2025 · strength 0.34
  8. Yaqing Zhang · 3 shared papers, 2019–2022 · strength 0.31
  9. Muxing Li · 2 shared papers, 2021 · strength 0.28
  10. Bin Jiang · 2 shared papers, 2021 · strength 0.28
  11. Howard C. Crawford · 3 shared papers, 2019–2022 · strength 0.28
  12. Rosa Elena Menjivar · 2 shared papers, 2021–2023 · strength 0.24
  13. Eileen S. Carpenter · 2 shared papers, 2021–2023 · strength 0.24
  14. Anguraj Sadanandam · 2 shared papers, 2021–2023 · strength 0.24
  15. Seth Boyer · 2 shared papers, 2022 · strength 0.24
  16. Rima Singh · 2 shared papers, 2022 · strength 0.24
  17. Samuel Andrew Kerk · 2 shared papers, 2022 · strength 0.21
  18. Jiaqi Shi · 2 shared papers, 2019–2023 · strength 0.20
  19. Heather R. Christofk · 2 shared papers, 2020–2022 · strength 0.19
  20. Andrea Viale · 2 shared papers, 2020–2022 · strength 0.19
  21. Claus Jørgensen · 2 shared papers, 2020–2022 · strength 0.19
  22. Ben Z. Stanger · 2 shared papers, 2020–2022 · strength 0.19
  23. Huiqin Jiang · 1 shared paper, 2023 · strength 0.19
  24. Wei Guo · 1 shared paper, 2023 · strength 0.19
  25. Baishen Pan · 1 shared paper, 2023 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.